5807-09-0

Basic information

• Product Name: 4-morpholin-4-ylbutanoic acid
• Synonyms: 4-morpholin-4-ylbutanoic acid;4-MORPHOLINOBUTANOIC ACID;4-Morpholinebutyric acid;DF-533;4-morpholinebutanoic acid;4-morpholinobutyric acid;4-morpholin-4-ylbutanoic acid(SALTDATA: HCl)
• CAS NO: 5807-09-0
• Molecular Formula: C₈H₁₅NO₃
• Molecular Weight: 173.21
• Mol File: 5807-09-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 323.7°Cat760mmHg
• Flash Point: 149.6°C
• Appearance: /
• Density: 1.126g/cm³
• Vapor Pressure: 5.25E-05mmHg at 25°C
• Refractive Index: 1.481
• PKA: 4.41±0.10(Predicted)
• CAS DataBase Reference: 4-morpholin-4-ylbutanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-morpholin-4-ylbutanoic acid(5807-09-0)
• EPA Substance Registry System: 4-morpholin-4-ylbutanoic acid(5807-09-0)

Safety Data

• Hazardous Substances Data: 5807-09-0(Hazardous Substances Data)

Usage

General Description

4-morpholin-4-ylbutanoic acid, also known as 4-Morpholinebutanoic Acid or GABA-Morpholine Ester, is a chemical compound with the molecular formula C8H15NO4. It is a derivative of gamma-aminobutyric acid (GABA), an important neurotransmitter in the central nervous system that regulates neuronal excitability. 4-morpholin-4-ylbutanoic acid is a GABA analogue and is believed to have potential therapeutic applications in the treatment of various neurological and psychiatric disorders, including anxiety, depression, and epilepsy. It has been studied for its potential anti-convulsant and anxiolytic properties, and is also being investigated as a possible drug candidate for the treatment of drug addiction and withdrawal symptoms. 4-morpholin-4-ylbutanoic acid is of interest to researchers and pharmaceutical companies for its potential as a novel and effective therapeutic agent targeting GABAergic signaling pathways.

InChI:InChI=1/C8H15NO3/c10-8(11)2-1-3-9-4-6-12-7-5-9/h1-7H2,(H,10,11)

Upstream product

• 5471-53-4 methyl 4-morpholinobutanoate 
• 88217-57-6 3-morpholin-4-ylpropionic acid ethyl ester 

Downstream Products

• 252936-34-8 N-[2-({2-[(6-amino-5-nitro(2-pyridyl))amino]ethyl}amino)-4-(2,4-dichlorophenyl)pyrimidin-5-yl]-4-morpholin-4-ylbutanamide 
• 1620517-08-9 4-morpholino-N-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenyl)butanamide 

Relevant articles and documents

Drugs derived from cannabinoids. 2. Basic esters of nitrogen and carbocyclic analogs

Various basic esters of nitrogen (2) and carbocyclic (3 and 4) analogs of cannabinoids were synthesized using dicyclohexylcarbodiimide in methylene chloride. The compounds in the three series were studied in selected pharmacological tests in mice, rats, dogs, and cats. It was shown that making the basic ester from the phenol retains biological activity and can lead to a greater selectivity of action, particularly the antinociceptive activity. The most interesting esters were 5, 6, 10, and 14 in the nitrogen analogs series and 19 and 20 in the carbocyclic series. Compound 5 was more potent than codeine in the writhing, hot plate, and tail flick tests and is at present undergoing clinical testing. Compound 20 was very potent in the mouse audiogenic seizure test and is of interest as an anticonvulsant agent.

Development of a series of bis-triazoles as G-quadruplex ligands

Maintenance of telomeres-specialized complexes that protect the ends of chromosomes-is provided by the enzyme complex telomerase, which is a key factor that is activated in more than 80% of cancer cells, but absent in most normal cells. Targeting telomere maintenance mechanisms could potentially halt tumour growth across a broad spectrum of cancer types. Telomeric ends of chromosomes consist of noncoding repeat sequences of guanine-rich DNA. These G-rich ends can fold into structures called G-quadruplexes. Stabilization of G-quadruplexes by small binding molecules called G4 ligands can prevent telomerase enzyme from maintaining telomere integrity in cancer cells. G-quadruplexes can exist in other parts of the genome too, especially within promoter sequences of oncogenes, and also be interesting drug targets. Here, we describe the development of a new series of novel bis-triazoles, designed to stabilize G-quadruplex structures selectively as G4 ligands. FRET assays showed two compounds to be moderately effective G4 binders, with particular affinity for the quadruplex formed by the Hsp90a promoter sequence, and good selectivity for G-quadruplex DNA vs. duplex DNA. However, CD spectroscopy failed to provide any information about the folding topology of the human telomeric G-quadruplex resulting from its interaction with one of the ligands. All the new ligands showed potent cell growth inhibitory properties against human colon and pancreatic cancer cell lines, as evidenced by the MTT assay; notably, they were more potent against cancer cells than in fetal lung fibroblasts. Docking studies were performed to rationalize the affinity of these ligands for binding to the telomeric parallel G-quadruplex DNA.

NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.